Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Albireo Pharma Inc (ALBO)

Albireo Pharma Inc (ALBO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 458,454
  • Shares Outstanding, K 19,279
  • Annual Sales, $ 8,310 K
  • Annual Income, $ -107,630 K
  • 60-Month Beta 1.46
  • Price/Sales 58.45
  • Price/Cash Flow N/A
  • Price/Book 2.67
Trade ALBO with:

Options Overview Details

View History
  • Implied Volatility 78.19%
  • Historical Volatility 47.95%
  • IV Percentile 83%
  • IV Rank 45.30%
  • IV High 103.82% on 07/19/21
  • IV Low 56.97% on 11/16/21
  • Put/Call Vol Ratio 0.72
  • Today's Volume 50
  • Volume Avg (30-Day) 141
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 133
  • Open Int (30-Day) 158

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 6 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/21
See More
  • Average Estimate -1.51
  • Number of Estimates 5
  • High Estimate -0.93
  • Low Estimate -2.11
  • Prior Year -1.30
  • Growth Rate Est. (year over year) -16.15%

Price Performance

See More
Period Period Low Period High Performance
1-Month
22.69 +0.53%
on 11/29/21
31.40 -27.36%
on 11/08/21
-6.41 (-21.94%)
since 10/29/21
3-Month
22.69 +0.53%
on 11/29/21
33.00 -30.88%
on 09/23/21
-7.01 (-23.51%)
since 08/27/21
52-Week
22.69 +0.53%
on 11/29/21
43.41 -47.45%
on 02/09/21
-13.50 (-37.18%)
since 11/27/20

Most Recent Stories

More News
Albireo Pharma (ALBO) Reports Q3 Loss, Lags Revenue Estimates

Albireo Pharma (ALBO) delivered earnings and revenue surprises of -333.33% and -83.59%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

ALBO : 22.81 (-4.08%)
Albireo Reports Q3 Financial Results and Business Update

– Bylvay™ (odevixibat) approved in the U.S. and Europe, partial Q3 ’21 revenue of $1.1 million– – ASSERT & BOLD Phase 3 studies enrolling, on track...

ALBO : 22.81 (-4.08%)
Albireo to Report Third Quarter 2021 Financial Results on November 4

— Conference call and webcast to be held at 10:00 a.m. ET — ...

ALBO : 22.81 (-4.08%)
Albireo to Showcase New Data at AASLD The Liver Meeting® 2021

– Seven abstracts accepted highlighting data in pediatric cholestatic and viral liver diseases – – Phase 3 Bylvay™ (odevixibat) data presentations on...

ALBO : 22.81 (-4.08%)
Albireo Announces Exclusive Licensing Agreement with Jadeite Medicines for Bylvay™ (odevixibat) in Japan

– Agreement to accelerate commercialization of Bylvay™ (odevixibat) in Japan, a significant market for PFIC, Alagille syndrome and biliary atresia – –...

ALBO : 22.81 (-4.08%)
Albireo Recognizes PFIC Awareness Day 2021

BOSTON, Oct. 05, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid...

ALBO : 22.81 (-4.08%)
Albireo Announces Bylvay® (odevixibat) Now Available in Germany

– Listed on the German national price list and all pharmacy software programs –

ALBO : 22.81 (-4.08%)
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

BOSTON, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Albireo Pharma, Inc. (Nasdaq: ALBO), a rare pediatric liver disease company developing novel bile acid modulators, today announced the grant of inducement stock...

ALBO : 22.81 (-4.08%)
Albireo Receives UK MHRA Approval of Bylvay® (odevixibat)

– Bylvay now approved in U.S., EU and UK as first drug treatment for patients with PFIC –

ALBO : 22.81 (-4.08%)
Albireo Sells Priority Review Voucher (PRV) for $105 Million

– PRV was granted to Albireo with the FDA approval of Bylvay TM (odevixibat) in July –

ALBO : 22.81 (-4.08%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell and ranks in the Top 1% of all short term signal directions.

Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More Share

Business Summary

Albireo Pharma, Inc. is a biopharmaceutical company. It focused on the development of novel bile acid modulators to treat orphan pediatric liver diseases and other liver and gastrointestinal diseases and disorders. Albireo Pharma Inc., formerly known as BIODEL INC., is based in Boston, United States....

See More

Key Turning Points

3rd Resistance Point 25.24
2nd Resistance Point 24.70
1st Resistance Point 23.76
Last Price 22.81
1st Support Level 22.28
2nd Support Level 21.74
3rd Support Level 20.80

See More

52-Week High 43.41
Fibonacci 61.8% 35.49
Fibonacci 50% 33.05
Fibonacci 38.2% 30.61
Last Price 22.81
52-Week Low 22.69

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar